Autolus Limited

64 patents currently held · Updated Nov 15, 2026

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Oct 2034

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 18, 2027
The maintenance fee for Cell (US 11,701,386) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
1 fee due Apr 29, 2027
The maintenance fee for Chimeric Antigen Receptor (CAR) Comprising a CD19-Binding Domain (US 10,457,730) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
2 fees due May 14 to 19, 2027 · next May 14
1 fee due Jun 26, 2027
The maintenance fee for Car T-Cells Comprising Transcriptional Circuits (US 11,851,672) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
3 fees due Jul 23 to 30, 2027 · next Jul 23
1 fee due Aug 20, 2027
The maintenance fee for Method of Preparing T Cells with Increased Activity (US 11,903,967) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
4 fees due Oct 2 to 23, 2027 · next Oct 2
2 fees due Nov 14, 2027

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 10,160,794	Chimeric Antigen Receptor In force Term ends Oct 10, 2034 · High confidence	In force	Term ends Oct 10, 2034	High confidence
US 10,919,951	Chimeric Antigen Receptor In force Ends no later than Oct 10, 2034 · Medium confidence	In force	Ends no later than Oct 10, 2034	Medium confidence
US 10,172,885	Cell In force Term ends Nov 21, 2034 · High confidence	In force	Term ends Nov 21, 2034	High confidence
US 11,385,233	Methods of depleting malignant T-cells. In force Term ends Mar 5, 2035 · Medium confidence	In force	Term ends Mar 5, 2035	Medium confidence
US 11,885,806	Method for Depleting Malignant T-Cells In force Ends no later than Mar 5, 2035 · Low confidence	In force	Ends no later than Mar 5, 2035	Low confidence
US 11,885,807	Method for Depleting Malignant T-Cells In force Ends no later than Mar 5, 2035 · Low confidence	In force	Ends no later than Mar 5, 2035	Low confidence
US 11,982,672	Methods In force Ends no later than Mar 5, 2035 · Low confidence	In force	Ends no later than Mar 5, 2035	Low confidence
US 11,982,673	Methods In force Ends no later than Mar 5, 2035 · Low confidence	In force	Ends no later than Mar 5, 2035	Low confidence
US 10,975,162	Chimeric Antigen Receptor In force Term ends Mar 19, 2035 · High confidence	In force	Term ends Mar 19, 2035	High confidence
US 10,172,886	Cell In force Term ends Aug 15, 2035 · High confidence	In force	Term ends Aug 15, 2035	High confidence

10 of 64 patents shown.

Pro members see all 64.

Pro members: see all 64 patents

Also on record, not counted in the 64: 1 patent in force now held by others · 8 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

27 pending · 7 abandoned · 35 no status recorded

List them